Lasa Supergenerics Ltd

Chairman

Dear Stakeholders,

I take this opportunity to Share with you the company's performance for the financial year ended March 31, 2023, with this Annual Report. The year under review posed several challenges as we saw al volatility intertwined with economic uncertainty geopolitic even as the world was coming out of the pandemic-imposed restrictions. The war in Europe was a key driver of the uncertainty which was significantly felt during the first half of the year even as turbulence continues Rise in the price of Gas, Fuel and Food due to disruption in the global trade on account of Russia-Ukraine translating into rising inflation had also somewhere affected Indian Pharma Industries, yes, we have seen global economic recovery in the later part of the year.

Biggest challenge which is still disturbing our credibility and of Section 7 application before Hon'ble NCLT morale is filing by Bank of Baroda for alleged default in External Commercial

Borrowings which is completely baseless and the credibility of the company is hampered by such act of Bank, whereby we are fully prepared to clear entire settled dues in one go however, the main agenda of Bank behind such act is still unknown.

We have the potential and passion to achieve way higher than what we are already delivering, and upon settlement of ongoing disruption by bank in NCLT, we will set the new records in the history of Lasa since the opportunities are waiting at our doorstep.

This year I chose to remain neutral with my comments and speak only with our achievements. leading players in the manufacturing of APIs, with a well-established brand OurCompanycontinue known for its high-quality products amongst various customers.

We have definitelydeliveredgoodsetofnumbersintheprevailingsituation,negative bottom is mainly due to the exceptional items which majorly includes impairment value of our Mahad Unit as per IND AS.

During the year Total Income Stood at Rs131.37 Crores.

The Company reported Loss before Interest, Tax,Depreciationand (EBITDA) of Amortization Rs (4.79) crore in FY23. The Company's EBITDA margin stood at -3.65% in FY23. The Company reported a decrease in its PATto of exceptional Rs (38.62)croreforFY23whichwas mainlydueto absorption items during the year.

The outflow of finance cost continues to be Zero in FY23 in line with company's vision. The Current Ratio improved from 1.48 in FY22 to 0.92 in FY23.

We continue to be in state of evolutionthrough a strong drive for improvement while remaining focused on quality, compliance, talent, development and effective risk management. I place my sincere gratitude towards our Shareholders, Investors, Employees, Customers, Suppliers, Bankers, Regulators and all business associates and thank you all for having your confidenceinLASA Family.